Page 53 - 《中国药房》2025年16期
P. 53

参考文献                                               [14]  中国抗癌协会癌症康复与姑息治疗专业委员会,中国抗
          [ 1 ]  BRAY F,LAVERSANNE M,SUNG H,et al. Global can‐    癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支
              cer  statistics  2022:GLOBOCAN  estimates  of  incidence   持治疗专业委员会,等. 中国抗肿瘤治疗相关恶心呕吐
              and mortality worldwide for  36  cancers in 185  countries  预防和治疗指南:2023 版[J]. 中华肿瘤杂志,2024,46
              [J]. CA Cancer J Clin,2024,74(3):229-263.          (6):481-501.
          [ 2 ]  VASAN N,BASELGA J,HYMAN D M. A view on drug   [15]  钱隽,郁韵秋. 液相色谱-质谱联用分析紫杉醇和多西他
              resistance in cancer[J]. Nature,2019,575(7782):299-309.  赛中流动相体系的优化[J]. 复旦学报(医学版),2012,39
          [ 3 ]  陈伟,王燕婷,王宇,等. 紫杉类抗肿瘤药物药学服务中                      (6):605-610.
              国专家共识[J]. 中国医院用药评价与分析,2022,22                  [16]  HAAK B W,LANKELMA J M,HUGENHOLTZ F,et al.
              (12):1409-1427.                                     Long-term impact of oral vancomycin,ciprofloxacin and
          [ 4 ]  RAPOPORT  B  L,HERRSTEDT  J,SNOW  R  C,et  al.   metronidazole on the gut microbiota in healthy humans[J].
                                                                  J Antimicrob Chemother,2019,74(3):782-786.
              2023  updated  MASCC/ESMO  consensus  recommenda‐
              tions:prevention  of  nausea  and  vomiting  following   [17]  GUO J,XU Y,CHEN L J,et al. Gut microbiota and host
              multiple-day chemotherapy,high-dose chemotherapy,and   CYP450s  co-contribute  to  pharmacokinetic  variability  in
                                                                  mice with non-alcoholic steatohepatitis:effects vary from
              breakthrough nausea and vomiting[J]. Support Care Can‐
                                                                  drug to drug[J]. J Adv Res,2022,39:319-332.
              cer,2023,32(1):36.
                                                             [18]  TOGAO M,KAWAKAMI K,OTSUKA J,et al. Effects of
          [ 5 ]  NATALE J J,SPINELLI T,CALCAGNILE S,et al. Drug-
              drug interaction profile of components of a fixed combina‐  gut microbiota on in vivo metabolism and tissue accumula‐
                                                                  tion of cytochrome P450 3A metabolized drug:midazolam
              tion of netupitant and palonosetron:review of clinical data
                                                                  [J]. Biopharm Drug Dispos,2020,41(7):275-282.
              [J]. J Oncol Pharm Pract,2016,22(3):485-495.
                                                             [19]  FLOWERS S A,BHAT S,LEE J C. Potential implications
          [ 6 ]  DEB S,HOPEFL R. Simulation of drug-drug interactions
                                                                  of  gut  microbiota  in  drug  pharmacokinetics  and  bioavai-
              between  breast  cancer  chemotherapeutic  agents  and  anti‐
                                                                  lability[J]. Pharmacotherapy,2020,40(7):704-712.
              emetic drugs[J]. Daru,2023,31(2):95-105.
          [ 7 ]  DE  MARTEL  C,GEORGES  D,BRAY  F,et  al.  Global   [20]  AVIOR  Y,LEVY  G,ZIMERMAN  M,et  al.  Microbial-
                                                                  derived  lithocholic  acid  and  vitamin  K2  drive  the  meta‐
              burden  of  cancer  attributable  to  infections  in  2018:a
                                                                  bolic maturation of pluripotent stem cells-derived and fe‐
              worldwide  incidence  analysis[J].  Lancet  Glob  Health,
                                                                  tal hepatocytes[J]. Hepatology,2015,62(1):265-278.
              2020,8(2):e180-e190.
                                                             [21]  ISHII M,TODA T,IKARASHI N,et al. Gastrectomy in‐
          [ 8 ]  LI X C,GUO X L,LIU Y X,et al. Antibiotics affect the   creases the expression of hepatic cytochrome P450 3A by
              pharmacokinetics  of  n-butylphthalide  in  vivo  by  altering
                                                                  increasing  lithocholic  acid-producing  enteric  bacteria  in
              the  intestinal  microbiota[J].  PLoS  One,2024,19(6):
                                                                  mice[J]. Biol Pharm Bull,2014,37(2):298-305.
              e0297713.
                                                             [22]  WIKOFF W R,ANFORA A T,LIU J,et al. Metabolomics
          [ 9 ]  ZIMMERMANN  M, ZIMMERMANN-KOGADEEVA
                                                                  analysis reveals large effects of gut microflora on mamma‐
              M,WEGMANN  R,et  al.  Mapping  human  microbiome    lian blood metabolites[J]. Proc Natl Acad Sci USA,2009,
              drug  metabolism  by  gut  bacteria  and  their  genes[J].  Na‐
                                                                  106(10):3698-3703.
              ture,2019,570(7762):462-467.
                                                             [23]  MUN S J,LEE J,CHUNG K S,et al. Effect of microbial
          [10]  WALSH  J,GHEORGHE  C  E,LYTE  J  M,et  al.  Gut
                                                                  short-chain  fatty  acids  on  CYP3A4-mediated  metabolic
              microbiome-mediated  modulation  of  hepatic  cytochrome
                                                                  activation of human pluripotent stem cell-derived liver or‐
              P450  and  P-glycoprotein:impact  of  butyrate  and  fructo-  ganoids[J]. Cells,2021,10(1):126.
              oligosaccharide-inulin[J].  J  Pharm  Pharmacol,2020,72  [24]  BILEN M,DUFOUR J C,LAGIER J C,et al. The contri‐
              (8):1072-1081.                                      bution of culturomics to the repertoire of isolated human
          [11]  HUANG C,FENG S Y,HUO F J,et al. Effects of four an‐  bacterial  and  archaeal  species[J].  Microbiome,2018,
              tibiotics  on  the  diversity  of  the  intestinal  microbiota[J].   6(1):94.
              Microbiol Spectr,2022,10(2):e0190421.          [25]  NATIVIDAD  J  M,AGUS A,PLANCHAIS  J,et  al.  Im‐
          [12]  陈怡琴,杨娇,裴文丽,等 . 黑逍遥散对 APP/PS1 小鼠认                  paired aryl hydrocarbon receptor ligand production by the
              知障碍及其肠道菌群的调节作用[J/OL]. 中国实验方剂                        gut  microbiota  is  a  key  factor  in  metabolic  syndrome[J].
              学杂志,2025:1-18[2025-06-11]. https://link.cnki.net/doi/  Cell Metab,2018,28(5):737-749.e4.
              10.13422/j.cnki.syfjx.20250905.                [26]  ZHANG X T,HAN Y,HUANG W,et al. The influence of
          [13]  MANHAS D,BHATT S,RAI G,et al. Rottlerin renders a   the gut microbiota on the bioavailability of oral drugs[J].
              selective and highly potent CYP2C8 inhibition to impede   Acta Pharm Sin B,2021,11(7):1789-1812.
              EET formation for implication in cancer therapy[J]. Chem      (收稿日期:2025-03-04  修回日期:2025-06-29)
              Biol Interact,2023,380:110524.                                                      (编辑:张元媛)


          中国药房  2025年第36卷第16期                                              China Pharmacy  2025 Vol. 36  No. 16    · 1999 ·
   48   49   50   51   52   53   54   55   56   57   58